North America Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Country and Growth Forecast, 2024 - 2031
The North America Degenerative Disc Disease Treatment Market would witness market growth of 4.8% CAGR during the forecast period (2024-2031).
The US market dominated the North America Degenerative Disc Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $11,428.3 million by 2031. The Canada market is experiencing a CAGR of 7.1% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 6.2% during (2024 - 2031).
Degenerative Disc Disease (DDD) treatment encompasses various strategies aimed at managing symptoms, reducing pain, and improving spinal function in individuals affected by disc degeneration. DDD primarily affects the intervertebral discs, which act as cushions between the vertebrae in the spine. Over time, these discs may deteriorate due to wear and tear and stiffness, resulting in pain and decreased mobility. The treatment aims to alleviate symptoms, prevent further degeneration, and restore or maintain spinal function.
In addition, DDD treatment encompasses a range of therapeutic approaches aimed at managing symptoms, preserving spinal function, and improving the quality of life for affected individuals. Physical therapy programs are customized to strengthen supportive muscles, enhance flexibility, and encourage correct spinal alignment. Therapeutic exercises and techniques such as traction may alleviate pain and prevent further degeneration. Non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and pain relievers are frequently recommended for alleviating pain and inflammation related to DDD. These medications help reduce discomfort and improve mobility.
The Canadian healthcare sector's adoption of advanced medical technologies and minimally invasive surgical techniques enhances treatment outcomes for DDD patients. Innovations such as robotic-assisted surgeries and biologics contribute to improved patient recovery and satisfaction. Canada's emphasis on patient-centered care encourages the development of personalized treatment plans for individuals with degenerative disc disease. This approach integrates patient preferences and clinical outcomes, promoting the adoption of effective and tailored therapies. Also, Canada's aging population contributes to a higher prevalence of degenerative disc disease. This demographic shift creates a sustained demand for specialized treatments, including surgical and non-surgical interventions, driving growth in the degenerative disc disease treatment market. Thus, rising healthcare sector in North America will lead to increased demand for degenerative disc disease treatment in the region.
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drugs, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, Muscle Relaxants, and Steroids. Based on End Use, the market is segmented into Hospitals, Clinics, and Others. Based on Treatment Type, the market is segmented into Physical Therapy, Occupational Therapy, Special Exercises, Weight Loss Surgery, and Medications. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- B. Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
By Route of Administration
- Oral
- Injectable
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Acetaminophen
- Muscle Relaxants
- Steroids
- Hospitals
- Clinics
- Others
- Physical Therapy
- Occupational Therapy
- Special Exercises
- Weight Loss Surgery
- Medications
- US
- Canada
- Mexico
- Rest of North America
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Degenerative Disc Disease Treatment Market, by Route of Administration
- 1.4.2 North America Degenerative Disc Disease Treatment Market, by Drugs
- 1.4.3 North America Degenerative Disc Disease Treatment Market, by End Use
- 1.4.4 North America Degenerative Disc Disease Treatment Market, by Treatment Type
- 1.4.5 North America Degenerative Disc Disease Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. North America Degenerative Disc Disease Treatment Market by Route of Administration
- 4.1 North America Oral Market by Region
- 4.2 North America Injectable Market by Region
- Chapter 5. North America Degenerative Disc Disease Treatment Market by Drugs
- 5.1 North America NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
- 5.2 North America Acetaminophen Market by Country
- 5.3 North America Muscle Relaxants Market by Country
- 5.4 North America Steroids Market by Country
- Chapter 6. North America Degenerative Disc Disease Treatment Market by End Use
- 6.1 North America Hospitals Market by Country
- 6.2 North America Clinics Market by Country
- 6.3 North America Others Market by Country
- Chapter 7. North America Degenerative Disc Disease Treatment Market by Treatment Type
- 7.1 North America Physical Therapy Market by Country
- 7.2 North America Occupational Therapy Market by Country
- 7.3 North America Special Exercises Market by Country
- 7.4 North America Weight Loss Surgery Market by Country
- 7.5 North America Medications Market by Country
- Chapter 8. North America Degenerative Disc Disease Treatment Market by Country
- 8.1 US Degenerative Disc Disease Treatment Market
- 8.1.1 US Degenerative Disc Disease Treatment Market by Route of Administration
- 8.1.2 US Degenerative Disc Disease Treatment Market by Drugs
- 8.1.3 US Degenerative Disc Disease Treatment Market by End Use
- 8.1.4 US Degenerative Disc Disease Treatment Market by Treatment Type
- 8.2 Canada Degenerative Disc Disease Treatment Market
- 8.2.1 Canada Degenerative Disc Disease Treatment Market by Route of Administration
- 8.2.2 Canada Degenerative Disc Disease Treatment Market by Drugs
- 8.2.3 Canada Degenerative Disc Disease Treatment Market by End Use
- 8.2.4 Canada Degenerative Disc Disease Treatment Market by Treatment Type
- 8.3 Mexico Degenerative Disc Disease Treatment Market
- 8.3.1 Mexico Degenerative Disc Disease Treatment Market by Route of Administration
- 8.3.2 Mexico Degenerative Disc Disease Treatment Market by Drugs
- 8.3.3 Mexico Degenerative Disc Disease Treatment Market by End Use
- 8.3.4 Mexico Degenerative Disc Disease Treatment Market by Treatment Type
- 8.4 Rest of North America Degenerative Disc Disease Treatment Market
- 8.4.1 Rest of North America Degenerative Disc Disease Treatment Market by Route of Administration
- 8.4.2 Rest of North America Degenerative Disc Disease Treatment Market by Drugs
- 8.4.3 Rest of North America Degenerative Disc Disease Treatment Market by End Use
- 8.4.4 Rest of North America Degenerative Disc Disease Treatment Market by Treatment Type
- Chapter 9. Company Profiles
- 9.1 Medtronic PLC
- 9.1.1 Company overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expenses
- 9.1.5 Recent strategies and developments:
- 9.1.5.1 Partnerships, Collaborations, and Agreements:
- 9.1.5.2 Trail and Approvals:
- 9.1.6 SWOT Analysis
- 9.2 AstraZeneca PLC
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
- 9.3 Pfizer, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional & Segmental Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 SWOT Analysis
- 9.4 Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 Recent strategies and developments:
- 9.4.5.1 Partnerships, Collaborations, and Agreements:
- 9.4.5.2 Acquisition and Mergers:
- 9.4.6 SWOT Analysis
- 9.5 Eli Lilly And Company
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Regional Analysis
- 9.5.4 Research & Development Expenses
- 9.5.5 SWOT Analysis
- 9.6 Spine Wave Inc.
- 9.6.1 Company Overview
- 9.7 B. Braun Melsungen AG (Aesculap, Inc.)
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expenses
- 9.7.5 SWOT Analysis
- 9.8 DiscGenics, Inc.
- 9.8.1 Company Overview
- 9.9 Spine BioPharma Inc.
- 9.9.1 Company Overview
- 9.10. Stryker Corporation
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Segmental and Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook